CN116059263A - 一种富硒破壁灵芝孢子颗粒及其制备方法 - Google Patents
一种富硒破壁灵芝孢子颗粒及其制备方法 Download PDFInfo
- Publication number
- CN116059263A CN116059263A CN202111281230.6A CN202111281230A CN116059263A CN 116059263 A CN116059263 A CN 116059263A CN 202111281230 A CN202111281230 A CN 202111281230A CN 116059263 A CN116059263 A CN 116059263A
- Authority
- CN
- China
- Prior art keywords
- ganoderma lucidum
- selenium
- enriched
- powder
- wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 84
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 84
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 30
- 239000011669 selenium Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000002245 particle Substances 0.000 title claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 46
- 238000000227 grinding Methods 0.000 claims abstract description 44
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 229920001525 carrageenan Polymers 0.000 claims abstract description 14
- 229940113118 carrageenan Drugs 0.000 claims abstract description 14
- 235000010418 carrageenan Nutrition 0.000 claims abstract description 14
- 239000000679 carrageenan Substances 0.000 claims abstract description 14
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims abstract description 14
- 229920002261 Corn starch Polymers 0.000 claims abstract description 11
- 239000008120 corn starch Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 9
- 238000004806 packaging method and process Methods 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract 2
- 241000222336 Ganoderma Species 0.000 claims description 14
- 238000010298 pulverizing process Methods 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 2
- 230000036039 immunity Effects 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 238000012545 processing Methods 0.000 abstract description 7
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract description 2
- 229930003268 Vitamin C Natural products 0.000 abstract description 2
- 229930003427 Vitamin E Natural products 0.000 abstract description 2
- 229930003448 Vitamin K Natural products 0.000 abstract description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract description 2
- 230000003042 antagnostic effect Effects 0.000 abstract description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 2
- 229910001385 heavy metal Inorganic materials 0.000 abstract description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 abstract description 2
- 235000019155 vitamin A Nutrition 0.000 abstract description 2
- 239000011719 vitamin A Substances 0.000 abstract description 2
- 235000019154 vitamin C Nutrition 0.000 abstract description 2
- 239000011718 vitamin C Substances 0.000 abstract description 2
- 235000019165 vitamin E Nutrition 0.000 abstract description 2
- 229940046009 vitamin E Drugs 0.000 abstract description 2
- 239000011709 vitamin E Substances 0.000 abstract description 2
- 235000019168 vitamin K Nutrition 0.000 abstract description 2
- 239000011712 vitamin K Substances 0.000 abstract description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 abstract description 2
- 229940045997 vitamin a Drugs 0.000 abstract description 2
- 229940046010 vitamin k Drugs 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000001276 controlling effect Effects 0.000 description 9
- 238000007873 sieving Methods 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medical Informatics (AREA)
- Toxicology (AREA)
Abstract
本发明涉及一种富硒破壁灵芝孢子颗粒及其制备方法。属于灵芝资源的深加工产品。本发明就是为了解决现有灵芝粗加工阶段，有效成分大量流失等存在的问题。本发明将灵芝孢子粉和灵芝经超微粉碎，与硒化卡拉胶混合均匀，加玉米淀粉辅料，采用一步制粒法制粒，整粒，分装，包装。得到富硒破壁灵芝孢子颗粒。本发明的富硒破壁灵芝孢子颗粒的制备方法科学合理，其有效活性成分得到最大保留，质量稳定。其功能具有增强机体免疫功能、抗癌作用、抗氧化作用、拮抗有害重金属、调节维生素A、维生素C、维生素E、维生素K的吸收与利用、调节蛋白质的合成的功能、增强生殖功能等等。
Description
技术领域
本发明属于属于灵芝资源的深加工产品，尤其指一种利用富硒破壁灵芝孢子制作的颗粒剂及其制备方法。
背景技术
灵芝孢子是灵芝在生长成熟期，从灵芝菌褶中弹射出来的极其微小的卵形生殖细胞即灵芝的种子。灵芝孢子是活体生物体，灵芝孢子有二层由几丁质和葡聚糖构成的孢壁(多醣壁),且具有同心圆的层网结构, 质地坚韧, 耐酸碱, 极难氧化分解, 因此限制了人们对孢内有效物质的消化吸收。为了充分利用灵芝孢子内的有效物质, 必需对孢子粉进行破壁, 以便于人们对其有效物质的利用。科学实验证实，服用未破壁的孢子，只有10%~20%的有效成分能被人体吸收，而破壁之后有效成分吸收率在90%以上。灵芝孢子粉能增强非特异性免疫功能，提高体液免疫水平和细胞免疫水平,灵芝孢子粉能激活巨噬细胞的吞噬功能，对糖皮质激素有拮抗作用；灵芝孢子粉对D-氨基半乳糖所致肝损伤具有明显的拮抗作用,灵芝孢子粉对D-氨基半乳糖所致肝损害的保护作用；同时有明显的抑制血脂降血压等功效。硒有抗氧化作用，能够增强人体免疫力。缺硒使人体的免疫能力下降。将硒添加在破壁灵芝袍子粉内，可增强产品增强免疫的功能。东北是中国灵芝资源丰富，但是灵芝加工水平却一直处于在切片、粉碎等粗加工阶段，有效成分大量流失，严重制约了灵芝产业的发展。产业亟需新技术、新资源、新功能的灵芝产品调整产业结构，提高灵芝加工产业国内竞争力。国内鲜见富硒破壁灵芝孢子粉相关产品，相关技术领域处于空白状态。
发明内容
l、发明目的：本发明提供了一种富硒破壁灵芝孢子颗粒及其生产工艺，其目的就是为了解决现有灵芝粗加工阶段，有效成分大量流失或人体不能有效吸收等存在的问题。硒化卡拉胶作为多糖类有机硒营养强化剂，可增强产品增强免疫的功能。
2、技术方案
一种富硒破壁灵芝孢子颗粒，其特征在于它是由下列原料按重量比制备而成：灵芝孢子粉30~60份，灵芝15~30份、硒化卡拉胶0.05~0.1份、玉米淀粉5.0份~25份。
一种如权利要求1所述的富硒破壁灵芝孢子颗粒制备方法，其特征在于富硒破壁灵芝孢子颗粒制剂按如下步骤进行制备：
（1）取灵芝孢子粉30~60份进行低温超微粉碎，粉碎温度10~40℃，超微粉碎功率为800～1500W，粉碎时间20～45分钟，粉碎次数1~3次，备用；
（2）另取灵芝15~30份进行粗粉碎，粉碎时间20~40min，控制灵芝粉碎粒径0.5～1.0mm范围，进行烘干，温度控制在75~80℃，水分控制在8%以下。烘干后再次进行2~4次粉碎，每次粉碎时间20~45min，粉末过4号筛，制成超细灵芝粉备用。
（3）取(2)中灵芝粉末进行超微粉碎，粉碎温度10~40℃，冷却温度，超微粉碎功率为800～1500W，粉碎时间20～35分钟，粉碎次数2~4次，备用。
（3）将(1)与(3)粉末进行合并，加入硒化卡拉胶0.05~0.1份，混合30～50min，混匀后加入玉米淀粉5.0份~25份，采用一步制粒法制粒，整粒，分装，包装。
如上所述富硒破壁灵芝孢子颗粒制剂的制备方法，其特征在于：将灵芝孢子粉和灵芝粉末进行超微粉碎，粉碎温度10℃，粉碎功率1500W，粉碎次数2次，每次时间为20min。
说明书
3优点
本发明富硒破壁灵芝孢子颗粒每日服用两次，早晚各一次，一次3～6g，服用后提高机体的免疫力，增强抗病能力，补气安神，还能降血压，控制血糖。
本发明灵芝功能主治：补气安神，止咳平喘。用于心神不宁，失眠心悸，肺虚咳喘，虚劳短气，不想饮食。
硒化卡拉胶是以天然红藻为原料制取的多糖类有机硒营养强化剂。具有抗癌作用、抗氧化作用、增强人体免疫力、拮抗有害重金属、调节维生素A、维生素C、维生素E、维生素K的吸收与利用、调节蛋白质的合成的功能、增强生殖功能等等。
本发明优点：灵芝及灵芝孢子粉经过低温超微粉碎，将最大限度的保留其有效成分，使其生物活性物质完全释放，有效提高了其有效成分的溶出率，以便于人们对其有效物质的利用。硒化卡拉胶作为多糖类有机硒营养强化剂，可增强产品增强免疫的功能。
具体实施方式
下面结合实施例对本发明进行进一步详细说明，但本发明的保护范围不受实施例所限。
实施例一
本发明制备方法如下：一种富硒破壁灵芝孢子颗粒，其特征在于它是由下列原料按重量比制备而成：灵芝孢子粉30份，灵芝15份、硒化卡拉胶0.05份、玉米淀粉10份。
本发明的硒破壁灵芝孢子片制备方法如下 ：
（1）取灵芝孢子粉进行低温超微粉碎，粉碎温度10℃，超微粉碎功率为1000W，每次粉碎时间20分钟，粉碎次数2次，过筛备用；
（2）另取灵芝15份进行粗粉碎，粉碎时间20min，控制灵芝粉碎粒径0.5～1.0mm范围，进行烘干，温度控制在75℃，水分控制在8%以下。烘干后再次进行2次粉碎，每次粉碎时间20min，粉末过4号筛，制成超细灵芝粉备用。
（3）取(2)中灵芝粉末进行超微粉碎，粉碎温度10℃，超微粉碎功率为1500W，粉碎时间30分钟，粉碎次数2次，备用。
（3）将(1)与(3)粉末进行合并，加入硒化卡拉胶0.05份，混合30min，混匀后加入玉米淀粉5.0份，采用一步制粒法制粒，整粒，分装，包装。
实施例二
本发明制备方法如下：一种富硒破壁灵芝孢子颗粒，其特征在于它是由下列原料按重量比制备而成：灵芝孢子粉60份，灵芝30份、硒化卡拉胶1.0份、玉米淀粉25份。
本发明的硒破壁灵芝孢子片制备方法如下 ：
（1）取灵芝孢子粉60份进行低温超微粉碎，粉碎温度10℃，超微粉碎功率为1500W，每次粉碎时间20分钟，粉碎次数2次，过筛备用；
（2）另取灵芝30份进行粗粉碎，粉碎时间30min，控制灵芝粉碎粒径0.5～1.0mm范围，进行烘干，温度控制在75℃，水分控制在8%以下。烘干后再次进行3次粉碎，每次粉碎时间25min，粉末过4号筛，制成超细灵芝粉备用。
（3）取(2)中灵芝粉末进行超微粉碎，粉碎温度10℃，超微粉碎功率为1500W，粉碎时间30分钟，粉碎次数2次，备用。
（4）将(1)与(3)粉末进行合并，加入硒化卡拉胶1.0份，混合35min，混匀后加入玉米淀粉5.0份，采用一步制粒法制粒，整粒，分装，包装。
实施例三
本发明制备方法如下：一种硒破壁灵芝孢子颗粒，其特征在于它是由下列原料按重量比制备而成：灵芝孢子粉40份，灵芝20份、硒化卡拉胶0.75份、玉米淀粉12份。
本发明的硒破壁灵芝孢子颗粒制备方法如下 ：
（1）取灵芝孢子粉40份进行低温超微粉碎，粉碎温度10℃，超微粉碎功率为1500W，每次粉碎时间20分钟，粉碎次数2次，过筛备用；
（2）另取灵芝20份进行粗粉碎，粉碎时间25min，控制灵芝粉碎粒径0.5～1.0mm范围，进行烘干，温度控制在75℃，水分控制在8%以下。烘干后再次进行3次粉碎，每次粉碎时间25min，粉末过4号筛，制成超细灵芝粉备用。
（3）取灵芝进行超微粉碎，粉碎温度10℃，超微粉碎功率为1500W，每次粉碎时间25分钟，粉碎次数4次，过筛备用。
（4）将(1)与(3)粉末进行合并，加入硒化卡拉0.75份，混合30min，混匀后加入玉米淀粉12份，采用一步制粒法制粒，整粒，分装，包装。
应当理解的是，对本领域普通技术人员来说，可以根据上述说明加以改进或变换，而所有这些改进和变换都应属于本发明所附权利要求的保护范围。
Claims (3)
1.一种富硒破壁灵芝孢子颗粒，其特征在于它是由下列原辅料按重量比制备而成：灵芝孢子粉30~60份，灵芝15~30份、硒化卡拉胶0.05~0.1份、玉米淀粉5.0份~25份。
2.一种如权利要求1所述的富硒破壁灵芝孢子颗粒制备方法，其特征在于富硒破壁灵芝孢子颗粒制剂按如下步骤进行制备：
（1）取灵芝孢子粉30~60份进行低温超微粉碎，粉碎温度10~40℃，超微粉碎功率为800～1500W，粉碎时间20～45分钟，粉碎次数1~3次，备用；
（2）另取灵芝15~30份进行粗粉碎，粉碎时间20min，控制灵芝粉碎粒径0.5～1.0mm范围，进行烘干，温度控制在75~80℃，水分控制在8%以下,烘干后再次进行2~4次粉碎，每次粉碎时间20~45min，粉末过4号筛，制成超细灵芝粉备用;
（3）取(2)中灵芝粉末进行超微粉碎，粉碎温度10~40℃，冷却温度，超微粉碎功率为800～1500W，粉碎时间20～35分钟，粉碎次数2~4次，备用;
（4）将(1)与(3)粉末进行合并，加入硒化卡拉胶0.05~0.1份，混合30～50min，混匀后加入玉米淀粉5.0份~25份，采用一步制粒法制粒，整粒，分装，包装。
3.如权利要求2所述富硒破壁灵芝孢子颗粒制剂的制备方法，其特征在于：将灵芝孢子粉和灵芝粉末进行超微粉碎，粉碎温度10℃，粉碎功率1500W，粉碎次数2次，每次时间为20min。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111281230.6A CN116059263A (zh) | 2021-11-01 | 2021-11-01 | 一种富硒破壁灵芝孢子颗粒及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111281230.6A CN116059263A (zh) | 2021-11-01 | 2021-11-01 | 一种富硒破壁灵芝孢子颗粒及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116059263A true CN116059263A (zh) | 2023-05-05 |
Family
ID=86180782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111281230.6A Pending CN116059263A (zh) | 2021-11-01 | 2021-11-01 | 一种富硒破壁灵芝孢子颗粒及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116059263A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105030848A (zh) * | 2015-07-10 | 2015-11-11 | 广西仙草堂制药有限责任公司 | 一种富硒灵芝保健品及其制备方法 |
| CN108497371A (zh) * | 2018-04-11 | 2018-09-07 | 兰州理工大学 | 一种富硒即食地苔片及其制备方法 |
| CN110840921A (zh) * | 2019-12-13 | 2020-02-28 | 福建省幸福生物科技有限公司 | 一种高压超临界co2灵芝萃取物及其制备工艺 |
| CN112385806A (zh) * | 2020-11-18 | 2021-02-23 | 深圳市名之洋生物科技有限公司 | 富硒魔芋食品及其制备方法 |
-
2021
- 2021-11-01 CN CN202111281230.6A patent/CN116059263A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105030848A (zh) * | 2015-07-10 | 2015-11-11 | 广西仙草堂制药有限责任公司 | 一种富硒灵芝保健品及其制备方法 |
| CN108497371A (zh) * | 2018-04-11 | 2018-09-07 | 兰州理工大学 | 一种富硒即食地苔片及其制备方法 |
| CN110840921A (zh) * | 2019-12-13 | 2020-02-28 | 福建省幸福生物科技有限公司 | 一种高压超临界co2灵芝萃取物及其制备工艺 |
| CN112385806A (zh) * | 2020-11-18 | 2021-02-23 | 深圳市名之洋生物科技有限公司 | 富硒魔芋食品及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 187****5045: "葡身康加硒（葡净康）", pages 2, Retrieved from the Internet <URL:https://max.book118.com/html/2018/0731/5221232242001303.shtm> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103960717B (zh) | 一种牡丹植物蛋白饮料及其制备方法 | |
| CN103960702B (zh) | 一种脱苦白果制备白果咀嚼片和泡腾片的方法 | |
| CN1215788C (zh) | 枸杞全粉冷冻升华干燥工艺 | |
| CN109007672A (zh) | 一种高蒜素大蒜粉的制备方法 | |
| JPH06105661A (ja) | 植物単細胞化食品の製造方法 | |
| CN105995348B (zh) | 秋葵膳食纤维饮料及其制备方法 | |
| CN116059263A (zh) | 一种富硒破壁灵芝孢子颗粒及其制备方法 | |
| CN102429881B (zh) | 一种苯溴马隆片的制备方法 | |
| CN104705630A (zh) | 杏鲍菇晶的制作方法 | |
| CN104177177A (zh) | 一种有机草莓绿色长效包膜肥料及其制备方法 | |
| CN104366646A (zh) | 一种洛神花保健晶的制作方法 | |
| WO2002021941A1 (fr) | Poudre ou graines d'algues marines au vinaigre et leur procede de production | |
| CN106616717A (zh) | 一种零添加破壁蜂花粉豆或蜂花粉片的制备工艺 | |
| CN111011772A (zh) | 一种超微粉碎制备龙眼超微粉的方法 | |
| CN109674009B (zh) | 一种银杏膨化粉加工方法 | |
| CN107156687A (zh) | 一种用牛骨制备纳米级牛骨粉的方法 | |
| CN103583763A (zh) | 一种利用热榨花生粕制备花生咖啡饮料的方法 | |
| CN106343132A (zh) | 一种蓝莓风味的乳酸菌压片糖果及其制备方法 | |
| CN106615679A (zh) | 以酱油渣为主料制备营养饲料的生猪饲喂方法 | |
| CN110463913A (zh) | 一种利用惰性气体制作海水稻米粉的方法 | |
| CN104642699A (zh) | 一种补气壮阳养生压片糖果的制作方法 | |
| JP2001211857A (ja) | イチョウ葉の粉粒加工物およびその製造方法 | |
| CN109198557A (zh) | 一种花生红皮的超微破壁粉的加工方法 | |
| CN106343138A (zh) | 一种鲜橙风味的乳酸菌压片糖果及其制备方法 | |
| CN104323230A (zh) | 破壁块菌含片及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20230505 |